期刊文献+

暴发性1型糖尿病的免疫学特征探讨 被引量:12

Immunological features of fulminant type 1 diabetes
原文传递
导出
摘要 目的探讨暴发性1型糖尿病患者的免疫学特征及其病因学意义。方法筛选暴发性1型糖尿病患者20例及其年龄、性别匹配的经典1型糖尿病患者40例。采用放射配体法检测谷氨酸脱羧酶抗体(GADA)、蛋白酪氨酸磷酸酶抗体(IA2A)和锌转运蛋白8抗体(ZnT8A);酶联免疫斑点法检测GAD反应性T细胞;直接测序法检测人类白细胞相关抗原(HIJA)DQ基因型。结果本组暴发性1型糖尿病患者8/20胰岛自身抗体阳性,其中7例GADA阳性,4例ZnT8A阳性,3例为GADA与ZnT8均阳性。3例起病初期GADA阳性者,于2年及3年后复查抗体转阴各1例,另1例3年后复查抗体滴度增高(0.34~1.46)。在6例暴发性1型糖尿病患者中3例有GAD反应性T细胞。暴发性1型糖尿病患者HLA—DQA1*0102-DQB1*0601和DQA1*03-DQB1*0401单体型频率较经典1型患者增高(P=0.005,P=0.035)。结论部分暴发性1型糖尿病患者存在体液或细胞免疫反应及HLA-DQ易感基因型,提示自身免疫反应可能参与暴发性1型糖尿病的发病过程。 Objective To investigate the immunological features of fulminant type 1 diabetes. Methods Twenty patients with fulmlnant type 1 diabetes (F1D) were recruited based upon the criteria proposed by Hanafusa, and 40 patients with classical type 1 diabetes were matched with age, gender and duration for comparison. GADA, IA2A and ZnTSA were determined with radioligand assay, and GAD- reactive T cells were measured by enzyme-linked immunospot(ELISPOT) assay. The HLA-DQ were analyzed by sequence-based genotyping (SBT). Results Eight of 20 patients with F1D were antobody-positive, including 7 GADA positive,4 ZnTSA positive, and 3 both GADA and ZnT8A positive. The index of 3 GADA positive patients were less than 0. 4 at first visit, two turned to be negative by two or three years. While the GADA index of the patient was 0. 343 at onset and increased to 1. 467 three years later. Among subjects with F1D(3/6) and classical type 1 diabetes (3/6), were recorded significant GAD-stimulated responses by ELISPOT assay. The frequencies of HLA-DQAI * 0102-DQB1 * 0601 and DQA1 * 03-DQB1 * 0401 were significantly higher in F1D than those in classical type 1 diabetes ( P = 0. 005, P = 0. 035, respectively). Conclusion Humoral and cellular immunoreactivity and susceptible HLA-DQ genotype exsisted in part of F1D patients, indicating autoimmunity may involve in the pathogenesis of F1D.
出处 《中华医学杂志》 CAS CSCD 北大核心 2009年第36期2544-2547,共4页 National Medical Journal of China
基金 基金项目:国家自然科学基金(30670991) 长沙市科技局重点项目(K061025-32) 国家高技术研究发展计划子课题项目(2006AA02A409) 国家重点基础研究发展计划子课题项目(2006CB503901) 国家自然科学基金中港合作项目(30831160518)志谢中国暴发性1型糖尿病研究协作组成员:北京协和医院(肖新华)、广西医科大学第一附属医院(刘红)、贵阳医学院附属医院(张松)、湖南省株洲市一医院(林小红)、南华大学附属第一医院(文芳)、南华大学附属第二医院(王建平)、南京大学鼓楼医院(朱大龙、李莉蓉)、江苏省宁波市北仑人民医院(王小玲)、温州医学院附属第一医院(汪大望)
关键词 糖尿病 1型 自身抗体 免疫 细胞 Diabetes mellitus, type 1 Autoantibodies Immunity, cellular
  • 相关文献

参考文献12

  • 1Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related ant/bodies, osaka IDDM study group. N Engl J Med ,2000,342:301-307.
  • 2Shimada A, Morimoto J, Kodama K, et al. T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes. Diabetes Care ,2002,25:635-636.
  • 3Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab,2007 ,3 :3645.
  • 4李霞,周智广,黄干,彭健,颜湘,王建平,杨琳.罗格列酮与胰岛素合用对LADA患者胰岛β细胞功能保护作用的初步观察[J].中国糖尿病杂志,2003,11(4):242-246. 被引量:63
  • 5Wang JP, Zhou ZG, Lin J, et al. Islet autoantibodies are associated with HLA-DQ genotypes in Han Chinese patients with type 1 diabetes and their relatives. Tissue Antigens,2007,70:369-375.
  • 6Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A,2007,104:17040-17045.
  • 7Iwaoka T. A case of fulminant type 1 diabetes with transiently positive anti-GAD antibodies. Endocr J,2003,50:225-231.
  • 8Sue M,Yoshihara A, Otani T, et al. Characteristics of fulminant type 1 diabetes mellitus. Med Sci Monit,2008,14 : CS97-101.
  • 9Sachdeva N, Asthana D. Cytokine quantitation : technologies and applications. Front Biosci ,2007 ,12 :4682-4695.
  • 10Kotani R, Nagata M, Imagawa A, et al. T lymphocyte response against pancreatic beta cell antigens in fulminant type 1 diabetes. Diabetologia ,2004,47 : 1285-1291.

二级参考文献9

  • 1王建民,周智广,文建新,伍汉文,ThomasDyrberg.谷氨酸脱羧酶(GAD_(65))自身抗体的放射配体检测法[J].中国糖尿病杂志,1997,5(2):85-88. 被引量:21
  • 2[1]Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab,2000,85:76-80.
  • 3[2]Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol, 2001, 169:453-459.
  • 4[4]Johansson BL, Brog K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med, 2000, 17:181-189.
  • 5[5]Di Mario U, Dotta F. Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabete Metab Rev, 1993.245-249.
  • 6[6]Kobayashi T, Nakanishi K, Murase T , et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes, 1996,45:622-626.
  • 7[7]Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve β cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci, 2002, 958:117-130.
  • 8[8]Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev,2002,18:114-117.
  • 9李霞,周智广,黄干,颜湘,杨琳,胡白瑛.谷氨酸脱羧酶抗体水平对两种成人隐匿性自身免疫糖尿病亚型的识别[J].中华内科杂志,2003,42(1):7-10. 被引量:49

共引文献62

同被引文献100

引证文献12

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部